omnadren 250

omnadren 250 is an inhibitor of carbonic anhydrase II. Because inhibition of carbonic anhydrase II is slowing down the formation of bicarbonate ions, followed by reduction with sodium and liquid transport, which reduces the intraocular fluid product in the ciliary body of the eye. The result is a reduction in the intraocular pressure (IOP).

When applied topically, omnadren 250 penetrates into the systemic circulation.
omnadren 250 adsorbed erythrocytes resulting in selective binding. The formation of a metabolite – N-dezetil omnadren 250, which also binds to carbonic anhydrase in red blood cells and accumulates. In the presence of omnadren 250 metabolite binds mainly to carbonic anhydrase I.
The plasma concentration omnadren 250 and its metabolite below the limit of quantification (<10 ng / ml). The half-life is 111 days. Plasma protein binding is approximately 60%.
omnadren 250 excreted mainly in urine in unchanged form. The primary metabolite (N-dezetilbrinzolamid) and low concentrations of other metabolites (N-dezmetoksipropila and O-desmethyl) are also found in urine.

Indications

Reduction of elevated intraocular pressure in:
– open-angle glaucoma;
– ocular hypertension.

Contraindications

Individual hypersensitivity to the drug;
Because Azopt ® and its metabolites are excreted mainly by the kidneys, it is not recommended for patients with severe renal impairment (creatinine clearance <30 mL / min).

Carefully

Use of the drug has not been studied in patients with narrow-angle glaucoma.
Use of the drug has not been studied in patients with severe liver disease, so such patients it should be administered with caution.
Sensitisation organism sulfonamides may occur in the event that drug is given again to the violation on its application instructions. In case of severe adverse reactions or signs of hypersensitivity of the drug should be discontinued.

Pregnancy and lactation

There are no adequate and well-controlled studies in pregnant women have not performed. Perhaps the use of the drug for the treatment of pregnant women for the purpose of the attending physician, if the expected therapeutic effect is greater than the risk of potential adverse effects to the fetus.
It is necessary to interrupt breast-feeding while using the drug.

Applications in Pediatrics

It is not recommended to use in children, because at the moment the safety and efficacy of the drug for children have not been established.

Dosing and Administration

Locally. Shake the vial before use.
Buried 1 drop into the conjunctival sac twice a day.

Side effects

In 5-10% of cases: blurred vision, bitter, sour or unusual taste in the mouth.
In 1-5% of cases: blepharitis, dermatitis, dry eye, foreign body sensation, headache, conjunctival hyperemia, eye discharge, discomfort eyes, keratitis, pain and itchy eyes, rhinitis.
Less than 1% of cases: local reactions – conjunctivitis, keratoconjunctivitis, diplopia, keratopathy, lacrimation, eye-strain, the crust on the edges of the eyelids; systemic reactions -. dizziness, hypertension, shortness of breath, chest pain, dry mouth, dyspepsia, nausea, diarrhea, back pain, sore throat, alopecia, allergic reactions, urticaria
Azopt ® is a sulfonamide. Since the local application systemic absorption of the drug takes place, side reactions may occur that are typical sulfonamides. Rarely, but there may be deaths due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant gepatonekroz, agranulocytosis, aplastic anemia and other disorders of hematopoiesis.

Overdose

There is no information about overdose symptoms when applied topically.
When taken orally, the drug can cause electrolyte imbalance, development of acidotic state, as well as disorders of the nervous system. It is necessary to control the levels of electrolytes (particularly potassium) and blood pH.

Interaction with other drugs

It is not recommended to use simultaneously with oral carbonic anhydrase inhibitors, because there is a possibility of systemic side amplification reactions.
Salicylates in high doses increase the risk of systemic side effects.
Can be used in combination with other topical ophthalmic preparations, if necessary. In this case, the interval between their use should be at least 10 minutes.

special instructions

Bottle before use to shake.
The vial must be closed after each use.
Do not touch the pipette tip to any surfaces.
If the patient after treatment temporarily reduced sharpness of vision, it is not recommended to drive and engage in activities that require attention and response to his recovery.
The product contains the preservative benzalkonium chloride, which can be absorbed by contact lenses. Before applying the lens of the drug should be removed and set back no earlier than 15-20 minutes after instillation of the drug.

release Form

Eye drops 1%.
In 5 ml in a bottle-dropper «Droptainer ™» low density polyethylene.
1 bottle with instructions for use in a cardboard box. online anabolic steroids pharmacy

bradley martyn steroids

anabolic steroids buy online